EcoDrugPlus

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSPNAG00000013196
Gene Symbol: LOC108434824
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPNAG00000014749
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a-Like

Ensembl ID : ENSPNAG00000013538
Gene Symbol: LOC108411208
2 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPNAG00000024109
Gene Symbol: HTR4
3 Cross references
199 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a-Like

Ensembl ID : ENSPNAG00000007119
Gene Symbol: LOC108412811
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSPNAG00000020953
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPNAG00000014756
Gene Symbol: HTR7
4 Cross references
153 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPNAG00000002294
Gene Symbol: LOC108413899
3 Cross references
351 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSPNAG00000025648
Gene Symbol: LOC108414460
3 Cross references
155 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSPNAG00000027827
Gene Symbol: LOC108443934
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSPNAG00000029759
Gene Symbol: LOC108434904
3 Cross references
335 Possible Orthologues:

60s Ribosomal Protein L5-Like

Ensembl ID : ENSPNAG00000005904
Gene Symbol: LOC108436062
3 Cross references
521 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).